MK0524 Asthma POC Study (0524-008)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Asthma
Interventions
DRUG

Comparator: MK0524 + placebo

Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks

DRUG

Comparator: MK0524 + montelukast

Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks

DRUG

Comparator: placebo + montelukast

Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks

DRUG

Comparator: Placebo

During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00783601 - MK0524 Asthma POC Study (0524-008)(COMPLETED) | Biotech Hunter | Biotech Hunter